Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 10/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507847 | 1.00 | CA2 (0.42) | CA2CA12CA9CA1KDM4E | |
| SCHEMBL12215752 | 0.85 | CA2 (0.42) | CA2CA12CA9CA1PTGES2 | |
| SCHEMBL7433447 | 0.85 | CA2 (0.42) | CA2CA12CA9CA1KDM4E | |
| Hydrochloric Acid SCHEMBL2528481 | 0.83 | CA2 (0.41) | CA2CA12CA9CA1PTGES2 | |
| SCHEMBL2526456 | 0.83 | CA2 (0.41) | CA2CA12CA9CA1PTGES2 | |
| SCHEMBL14495279 | 0.83 | CA2 (0.41) | CA2CA12CA9CA1PTGES2 | |
| SCHEMBL13180014 | 0.82 | KDM4E (0.42) | KDM4EUSP2SMN1; SMN2 | |
| SCHEMBL29054624 | 0.81 | KDM4E (0.41) | KDM4EUSP2SMN1; SMN2 | |
| SCHEMBL6991911 | 0.78 | KDM4E (0.41) | CA2CA12CA9CA1KDM4E | |
| SCHEMBL18741085 | 0.78 | CA2 (0.53) | CA2CA12CA9CA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | CA2 3770/4885CA12 4849/4885CA9 4552/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | CA2 3770/4885CA12 4849/4885CA9 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.